Everest Medicines Expands NEFECON’s Reach in Asia

Everest Medicines Ltd. (HK:1952) has released an update.

Everest Medicines has announced the approval of its kidney disease drug NEFECON by the Taiwan Food and Drug Administration, marking a significant expansion in its treatment reach for IgA nephropathy, particularly in Asia where the condition is more prevalent. The company also highlighted promising results from a two-year clinical trial in China, showing substantial kidney function protection and reduction in proteinuria among patients. With approvals across several Asian regions, NEFECON is poised to become a leading treatment option for IgAN patients.

For further insights into HK:1952 stock, check out TipRanks’ Stock Analysis page.